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Angiotensin-converting enzyme 2 (ACE2) shares some homology with angiotensin-converting enzyme (ACE) but is not inhibited
by ACE inhibitors. The main role of ACE2 is the degradation of Ang II resulting in the formation of angiotensin 1–7 (Ang 1–7)
which opposes the actions of Ang II. Increased Ang II levels are thought to upregulate ACE2 activity, and in ACE2 deﬁcient mice
Ang II levels are approximately double that of wild-type mice, whilst Ang 1–7 levels are almost undetectable. Thus, ACE2 plays
a crucial role in the RAS because it opposes the actions of Ang II. Consequently, it has a beneﬁcial role in many diseases such as
hypertension,diabetes,andcardiovasculardiseasewhereitsexpressionisdecreased.Notsurprisingly,currenttherapeuticstrategies
for ACE2 involve augmenting its expression using ACE2 adenoviruses, recombinant ACE2 or compounds in these diseases thereby
aﬀording some organ protection.
1.Introduction
The renin-angiotensin system (RAS) is a signalling pathway
that acts as a homeostatic regulator of vascular function [1].
Its systemic actions include the regulation of blood pressure,
natriuresis, and blood volume control. However, the RAS
also plays an important local role, regulating regional
blood ﬂow and controlling trophic responses to a range
of stimuli. The RAS is composed of a number of diﬀerent
regulatory components and eﬀector peptides that facilitate
the dynamic control of vascular function, in both health and
disease (Figure 1). Many of these components have opposing
functions to accommodate a rapid but coordinated response
to speciﬁc triggers. For example, angiotensin I (Ang I) is
metabolised by the dipeptide carboxypeptidase, angiotensin-
converting enzyme (ACE) to form angiotensin II (Ang II)
and Ang II is metabolised by the carboxypeptidase, ACE2,
producing the vasodilator, angiotensin(1−7) (Ang 1–7) [2–4].
Historically, ACE and Ang II have been the key focus for
clinical interventions targeting the RAS and its pathogenic
actions. However, recent studies have also demonstrated
the importance of ACE2 in maintaining the balance of the
RAS. Indeed, in some settings, and the cardiovascular system
in particular, ACE2 may be more important than ACE in
regulating local levels of Ang II and Ang 1–7, and therein the
balance of RAS activation. For example, we have shown that
acquired or genetic deﬁciency of ACE2 results in increased
tissueandcirculatinglevelsofAngII[5,6]andreducedlev els
of Ang 1–7 [6]. By contrast, Ace KO mice have modestly
reduced circulating Ang II, while tissue levels are not sig-
niﬁcantly modiﬁed, possibly as substantial amounts of Ang
II are generated by non-ACE pathways, while degradation
pathways for Ang II are more limited [7]. This paper will
speciﬁcally examine the actions of ACE2 in the body and dis-
cuss their potential role in health and various disease states.
2. Angiotensin-ConvertingEnzyme (ACE2)
ACE2 is a type 1 integral membrane glycoprotein [8] that is
expressed and active in most tissues. The highest expression
of ACE2 is observed in the kidney, the endothelium, the
lungs, and in the heart [2, 8]. The extracellular domain of
ACE2 enzyme contains a single catalytic metallopeptidase
unit that shares 42% sequence identity and 61% sequence
similarity with the catalytic domain of ACE [2]. However,2 International Journal of Peptides
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Figure 1: Schematic representation of the renin-angiotensin
system (RAS) and the key balancing role of ACE2. Abbrevia-
tions, ACE: angiotensin-converting enzyme; ACE2: angiotensin-
converting enzyme 2; NEP: neprilysin; AT1: Ang II type 1 receptor;
AT2: Ang II type 2 receptor; PEP: prolyl endopeptidase; CAGE:
chymostatin-sensitive angiotensin II-generating enzyme.
unlike ACE, it functions as a carboxypeptidase, rather than
a dipeptidase, and ACE2 activity is not antagonized by
conventional ACE inhibitors [4]. The major substrate for
ACE2 appears to be (Ang II) [2–4], although other peptides
may also be degraded by ACE2, albeit at lower aﬃnity.
For example, ACE2 is able to cleave the C-terminal amino
acid from angiotensin I, vasoactive bradykinin (1–8), des-
Arg-kallidin (also known as des-Arg10 Lys-bradykinin) [2],
Apelin-13 and Apelin-36 [9] as well as other possible targets
[10]. The noncatalytic C-terminal domain of ACE2 shows
48%sequenceidentitywithcollectrin[11],aproteinrecently
shown to have an important role in neutral amino acid
reabsorption from the intestine and the kidney [12]. This is
highly consistent with ACE2’s actions as a carboxypeptidase,
as the removed amino acid then becomes available for
reabsorption. The cytoplasmic tail of ACE2 also contains
calmodulin-binding sites [13] which may inﬂuence shedding
of its catalytic ectodomain. In addition, ACE2 has also
been associated with integrin function, independent of its
angiotensinase activity.
3. ACE2 and Atherosclerosis
Abnormal activation of the RAS contributes to the develop-
mentandprogressionofatheroscleroticvasculardisease[14–
16]. Independent and additional to the induction of systemic
hypertension and vasoconstriction, Ang II has a number of
direct proatherosclerotic eﬀects on the vascular wall [17–19],
including promoting inﬂammation [20], endothelial dys-
function [21], oxidative stress, endothelial cell, and vascular
smooth muscle cell migration, growth, proliferation [22],
and thrombosis. By contrast, the major product of ACE2,
Ang 1–7, has a range of anti-inﬂammatory and antioxidant
eﬀects[23,24]thatopposethoseofAngIIinthevasculature.
Indeed, an infusion of Ang 1–7 is able to attenuate vascular
dysfunction and atherosclerosis in genetically susceptible
apolipoprotein E knockout (apoE KO) mice [25], possibly
by increased activation of the Mas receptor and the type 2
angiotensin receptor (AT2). It is thought that the balance of
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Figure 2: Increased plaque area accumulation in the aorta of
Apoe/Ace2 double KO mice when compared to control Apoe KO
mice [5]. ∗vs control Apoe KO mice P<0.05.
Ang II and Ang 1–7 represents an important driving factor
for vascular disease progression. Consequently, ACE2 is also
likely to play an important role in atherosclerotic plaque
development.Certainly,ACE2expressionisreducedinestab-
lished atherosclerotic plaques [26] and in proatherosclerotic
states, such as diabetes [27]. However, direct evidence for
ACE2 in the development and progression of atherosclerotic
plaques has only recently become available [5].
We have shown that in apoE KO mice, deﬁciency
of ACE2 is associated with increased plaque accumula-
tion (Figure 2), comparable to that observed following
angiotensin II infusion [19]. This possibly relates to an
increased proinﬂammatory responsiveness [5], as leukocyte
recruitment and adhesion to the nascent atherosclerotic
lesion is generally regarded as one of the ﬁrst steps toward
plaque formation. While a healthy endothelium does not in
general support binding of white blood cells, we show that
the aortic endothelium of apoE/Ace2 double KO mice shows
increased adhesion of labeled leukocytes [5]. In addition,
genetic ACE2 deﬁciency is associated with upregulation of
putative mediators of atherogenesis, such as cytokines and
adhesion molecules. The role of the RAS in these actions
is further emphasized by the ﬁnding that RAS blockade
is able to prevent atherogenesis in apoE/Ace2 double KO
mice. Such data emphasize the potential utility of ACE2
repletion as a strategy to reduce atherosclerosis, particularly
in combination with ACE inhibition and other interventions
to reduce activation of the RAS (see below).
4. ACE2 and Hypertension
Activation of the RAS is known to be a key mediator of
hypertension, and interventions to block RAS activation
are the most widely used of all blood pressure lowering
agents. The antihypertensive eﬃcacy of these agents is partly
mediated by their ability to reduce Ang II or its signalling.
However, the antihypertensive eﬀects of conventional RAS
blockade are also partly determined by the ability of both
ACE inhibitors and angiotensin receptor blockers (ARBs)International Journal of Peptides 3
to increase circulating levels of Ang 1–7 [28]. Moreover,
inhibiting the vascular actions of Ang 1–7 in spontaneously
hypertensive rats (SHRs) receiving RAS blockade, attenuates
the antihypertensive response to these agents [28, 29].
Given that the major source of Ang 1–7 is ACE2, this
data suggests that ACE2, consequently inﬂuences not only
the development of hypertension, but also potentially the
response to its treatment. Certainly, ACE2 expression is
abnormal in SHRs, in which one genetic component of
this phenotype tracks to the Ace2 locus. In addition, ACE2
deﬁciency is associated with modest systolic hypertension
[30], although the mouse genetic background signiﬁcantly
alters the cardiovascular phenotype [30–33]. Ace2 KO mice
also have a heightened hypertensive response to Ang II
infusion associated with exaggerated accumulation of Ang II
in the kidney [30].
The RAS and ACE2 are also implicated in the patho-
genesis of central hypertension. In particular, the rostral
ventrolateral medulla (RVLM) is a relay point that provides
supraspinal excitatory input to sympathetic preganglionic
neurons in the regulation of blood pressure. In the SHRs,
ACE2expressionisreducedintheRVLM[34],andpersistent
overexpression of ACE2 in the RVLM results in a signiﬁcant
attenuation of high blood pressure in this model [35, 36]. In
addition, injections of the ACE2 inhibitor MLN4760 into the
nucleustractussolitariireducereﬂexbradycardiainresponse
to the baroreceptor stimulation in rats [37], suggesting an
additional role for central ACE2 in controlling baroreceptor
responsiveness.
5.ACE2inHeartFailure
In addition to eﬀects on blood pressure, natriuresis and
atherogenesis, the RAS plays a critical pathophysiological
role in the maintaining and subsequently subverting cardiac
function in the setting of progressive heart failure [38]. The
cardiac RAS is upregulated in almost all models of cardiac
injury, including volume overload [39], myocardial infarc-
tion[40],andheartfailure[41].Asinthekidney,RASupreg-
ulation appears to be a homeostatic response to restore car-
diacfunction.Forexample,AngIIisaninotropicandgrowth
factor for cardiac myocytes, stimulating compensatory
hypertrophy [42] .A n gI Ii sa l s oi m p o r t a n ti nl e f tv e n t r i c u l a r
remodeling following myocardial infarction or with after-
load-induced cardiac hypertrophy[43]. However, in the long
term such actions lead to progressive functional loss and
cardiacﬁbrosis[42],asthesynthesisofextracellularmatrixis
increasedbyAngII[44].ThekeyroleofRASactivationinthe
development and progression of cardiac failure is supported
by ﬁndings in a number of diﬀerent models in which
blockade of the RAS was able to attenuate or prevent cardiac
damage, independent of blood pressure lowering [45].
In the heart, ACE2 represents the primary pathway for
the metabolism of Ang II [46, 47]. ACE2 deﬁciency in
mice results in early cardiac hypertrophy (Figure 3)[ 32]
andacceleratesadversepostmyocardialinfarctionventricular
remodeling [48]. Furthermore, this appears to be through
the activation of the NAPDH oxidase system with the
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Figure 3: Increased LV mass in Ace2 KO mice versus C57bl6 mice
(unpublished data). ∗vs control C57Bl6 mice, P<0.05.
p47(phox) subunit playing a critical role [49]. In some, but
not all models, ACE2 deﬁciency also results in progressive
cardiac ﬁbrosis with aging and/or cardiac pressure overload
[33, 50, 51]. Again, these changes are reversed following
treatment with ACE inhibitors or AT1 receptor blockers
[33, 50, 51] suggesting that the balance of ACE and ACE2
in the heart is an important driving factor for progressive
cardiac disease.
6.ACE2andChronicKidney Disease(CKD)
The RAS also plays an important role in renal physiology
and pathophysiology. In the adult kidney [2], ACE2 is
predominantly expressed in the proximal tubule at the
luminal brush border. Despite the presence of unopposed
ACE activity and elevated Ang II levels, both kidney function
and renal development are normal in the Ace2 knockout
mouse [33]. By comparison, ACE, angiotensinogen,a n dAT1
receptor deﬁciency results in a number of alterations in
kidney morphology [52]. This suggests that, at least in the
healthy state, ACE2 may have a limited role in regulating
renal development. However, the actions of ACE2 appear to
come into its own in states of RAS activation. This is much
like Ang 1–7, its major product, which shows very limited
renal eﬀects in the healthy state but profound beneﬁts in the
diabetickidneyandotherstatesassociatedwithrenaldamage
and activation [10, 53]. For example, ACE2 deﬁcient mice
have been reported to show increased age-related glomeru-
losclerosis in susceptible mouse models [54] and enhanced
renal Ang II-induced renal oxidative stress, resulting in
greater renal injury [55]. Similarly, in the diabetic kidney,
downregulationoftubularACE2(Figure 4)[27]isassociated
with albuminuria or tubular injury, while further inhibition
of ACE2 results in augmented renal damage [56, 57]. Indeed,
in most forms of CKD, including diabetes, expression of
ACE2 has been reported to be reduced in tubules. However,
some studies have reported that glomerular ACE2 expression
may be increased in human kidney disease [58]. It is possible
that this diﬀerential expression pattern of glomerular and4 International Journal of Peptides
(a) (b)
Figure 4: Reduced ACE2 expression (arrows) in renal cortical tubules of diabetic mice (b) when compared to control mice (a) [27].
tubular ACE2 is an important determinant for progressive
renal disease.
7.ACE2andthe Lung
RAS activity is intrinsically high in the lung, which is a
major source of ACE and therefore a major site of systemic
Ang II synthesis. ACE2 is also highly expressed in the
lung. Pulmonary ACE2 appears to have a role in regulating
the balance of circulating Ang II/Ang 1–7 levels. Ang II
induces pulmonary vasoconstriction in response to hypoxia,
which is important in preventing shunting in patients with
pneumonia or lung injury [59]. Locally increased Ang II
production also triggers increasing vascular permeability
facilitating pulmonary edema [60]. In Acute respiratory
distress syndrome (ARDS), the RAS appears crucial in
maintaining oxygenation, possibly as widespread lung injury
would otherwise result in complete pulmonary shutdown.
Certainly in ARDS models, ACE2 knockout mice displayed
more severe symptoms of this disease compared with wild-
type mice [60] while overexpression appears protective
(see below). Interestingly, ACE2 protein also appears to be
the entry-point receptor for the severe acute respiratory
syndrome (SARS) coronavirus [61, 62].
8.ReplenishingA CE2asaP otentialTherapeutic
Given the key role of ACE2, degrading Ang II and gen-
erating Ang 1–7, a number of studies have explored its
potential as a treatment strategy using human recombi-
nant ACE2 (rhACE2) or adenoviral (Ad)-ACE2 in animal
disease models. For example, overexpression of ACE2 in
human endothelial cells attenuates Ang II-induced oxidative
stress and subsequent increase in monocyte adhesion [63].
Similarly, in rabbits, a recombinant ACE2 expressing vector
stabilized atherosclerotic plaques induced by balloon injury
to the abdominal aorta [64]. Treatment with a lentiviral
vector containing ACE2 resulted in lower blood pressure in
hypertensive mice [65, 66] or following an Ang II infusion
[67]. Strategies to upregulate or replenish ACE2 are thought
to be beneﬁcial in diabetic nephropathy. For example, in
diabetes the replenishment of ACE2 with rhACE2 in a mouse
model of type 1 diabetes attenuated diabetic kidney injury
as well as reducing in blood pressure [68]. The use of (Ad)-
ACE2 has had similar beneﬁcial eﬀects in streptozotocin-
induced diabetes, where it was shown to attenuate glomeru-
lar mesangial cell proliferation, blood pressure, oxidative
stress, and ﬁbrosis [69].
In contrast to these studies, the potential utility of ACE2
supplementation in cardiac disease remains controversial.
The expression of ACE2 in the failing human heart is
generally increased [70–72], consistent with the ﬁnding of
elevated levels of Ang 1–7 in the same setting [73]. More
importantly, overexpression of ACE2 in cardiac myocytes
resulted in conduction disturbances by 2 weeks of age, ulti-
mately leading to lethal ventricular arrhythmias and severe
ﬁbrosis [74, 75]. This may be because ACE2 is not normally
expressed in high levels in myocytes, although it is present
in the endocardium and other cardiac cells. However, other
studiesusingtransgenicoverexpressionofcardiacACE2have
demonstrated partial protection in the heart from ischemia-
induced heart failure [76]. Indeed, more recent studies using
rhACE2 have shown beneﬁcial cardiac eﬀects [77]. However,
the indication for ACE2 that appears most likely to be ﬁrst
tested in the clinic is the treatment of ARDS. In murine
models, treatment with catalytically active recombinant
ACE2 protein improved the symptoms of acute lung injury
in wild-type mice as well as in ACE2 knockout mice [60].
Clinical trials in this often fatal condition are now underway.
Perhaps, the most clinically interesting, however, is the
potential for rACE2 to augment the vasculoprotective eﬀects
of ACE inhibition or ARBs, in the millions of patients
that take these agents, worldwide. In theory, this would be
achieved by preventing feedback escape for RAS blockade
or enhancing the generation of Ang 1–7, and subsequentInternational Journal of Peptides 5
signaling through the Mas receptor and or AT2 receptor.
Certainly, ACE2 inhibition attenuates the eﬀects of RAS
blockade, both in vitro [78] and in vivo [6]. But could
rACE2 make the response to conventional RAS blockade
more eﬀective or durable? The problem is that conventional
RAS blockade is highly eﬀective in animal models of vascular
and renal disease, meaning that it is diﬃcult to explore
the potential for further improvements. However, chronic
intravenous infusion of ANG-(1–7), or the nonpeptide mas
receptor agonist, AVE-0991, are able to improve salt-induced
suppression of endothelium-dependent vasodilatation in the
mesenteric arteries of male Sprague-Dawley rats, and these
actions are not modiﬁed by the angiotensin receptor blocker,
losartan [79], suggesting that the eﬀects of enhancing the
Ang 1–7 mas axis may be beneﬁcial, even in the setting
of conventional RAS blockade. Although it enhances the
generation of Ang 1–7, whether rACE2 can also provide
synergistic beneﬁts, remains to be established.
9.ACE2Augmenters:A New Kind
of Intervention
Rather than providing exogenous ACE2, an alternative
approach for augmenting ACE2 has been to increase its
endogenous expression. For example, in hypertensive SHRs,
all-trans retinoic acid, which increases ACE2 expression,
lowers blood pressure levels, and prevents vascular damage
[80]. Unfortunately retinoic acid has broader actions that
make its potential utility as a therapeutic limited. However,
compounds that increase activity of ACE2 could also be
beneﬁcial as a treatment in conditions where ACE2 activity
is decreased. One exemplar is xanthenone (XNT). This
molecule was selected following structure-based screening
on compounds that would stabilize the activated form
of ACE2, thereby enhancing its catalytic eﬃcacy [81]. In
experimental studies, this compound has been shown to
enhance ACE2 activity in a dose-dependent manner and
signiﬁcantly decreased blood pressure in both SHRs rats
and wild-type WKY rats [81]. Furthermore, improvements
in cardiac function and reversal of myocardial, perivascular,
and renal ﬁbrosis in the SHRs were also observed [81, 82].
XNT has also shown promise in treating pulmonary hyper-
tension (PH). For example, in a rat model of PH, treatment
with XNT was shown to reduce elevated right ventricular
systolic pressure, right ventricular hypertrophy, increased
pulmonaryvesselwallthickness,andinterstitial ﬁbrosis[83].
In a model of thrombus formation using SHRs and WKY
rats, XNT has also shown antithrombotic action, reducing
platelet attachment, and reducing thrombus formation [84].
This compound will not come to clinical trials because of
issues of solubility that restrict its formulation. However,
other drugs of the same class may prove more suitable.
10. Conclusion
ACE2 is an integral component of the RAS. It is highly
expressed in the vasculature, the kidney, lungs, and heart
where its actions on peptide signals balance and oﬀset
those of ACE. Its actions appear critical in a variety of
disease states, including hypertension, diabetes, ageing, renal
impairment, and cardiovascular disease. ACE2 deﬁciency
leads to modest physiological changes. However, in states
of RAS activation, the loss of ACE2 appears far more
important in the development and progression of disease. By
contrast, augmentation of ACE2 expression, either directly
with recombinant ACE2 or indirectly via agonists like XNT,
may have important beneﬁts relevant in the treatment of a
range of conditions.
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